News | May 17, 2022
BDR Pharma receives Rs. 685 crore of PE investment
Multiples is the first private equity (PE) investor in the company
Multiples is the first private equity (PE) investor in the company
It is developing the drug candidate to potentially treat immunological diseases
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
GenNext and Kiko Tech will provide sales and marketing, customer service, technical support, training, and related logistical efforts for Flash Oxidation Protein Footprinting Systems.
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
The campaign will be available in nine Indian languages namely Hindi, English, Odia, Marathi, Tamil, Telugu, Kannada, Malayalam and Bengali
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
Subscribe To Our Newsletter & Stay Updated
